Trial Profile
A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam When Given In Combination With Metronidazole, Compared With Meropenem, In Children From 3 Months To Less Than 18 Years Of Age With Complicated Intra-abdominal Infections (cIAIs)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary) ; Meropenem; Metronidazole
- Indications Intra-abdominal infections
- Focus Adverse reactions
- Sponsors AstraZeneca; Pfizer
- 19 Jul 2019 Results evaluating the safety, efficacy and pharmacokinetics of ceftazidime-avibactam plus metronidazole in children with Complicated Intra-abdominal Infections cIAI published in the Pediatric Infectious Disease Journal
- 16 Apr 2019 Results of PK/PD modelling and simulation to support paediatric dosing using data from NCT01893346, NCT02475733 and NCT02497781 trials, presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
- 24 Apr 2018 Results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases